In this captivating episode, Chadi shares the microphone with Nancy Olivieri, MD, professor of medicine, pediatrics, and public health science at the University of Toronto, to recount her famous clash with a pharmaceutical company (among other entities) that tried to silence her for reporting on adverse effects related to an experimental drug. Dr. Olivieri became famous for raising doubts about a drug that was being studied to treat patients with thalassemia. In great and juicy detail, Dr. Olivieri provides the timeline of events, including bouts with the company’s CEO as well as her own academic institution, and the legal battles that ensued.
N/A
Dr. Simrit Parmar, founder of Cellenkos, joins the show to discuss her journey from the lab to the biotech startup world, detailing the inspiration behind launching her company, the challenges of securing funding, and the resilience required to overcome rejections. She shares insights into Cellenkos’ lead product, its progress toward market approval, and the rigorous
Carol Rausch—a healthcare professional, cancer researcher, and former patient with lymphoma—shares how her journey from researcher to patient transformed her understanding of medical language. She discusses the impact of word choice on patients, why certain battle and war metaphors can be harmful, and how language used in clinical settings differs from what resonates with those
Drs. David Braun and Toni Choueiri join to discuss a groundbreaking Nature study on a personalized neoantigen vaccine for adjuvant renal cell carcinoma. They explore the inspiration behind the trial, how the vaccine was developed and administered, and its safety profile. The conversation also covers patient outcomes after 3-4 years, including immune responses and disease
